MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has signed a definitive agreement to acquire Mirus Bio for $600 million.   Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN, which play a critical role in the production of viral vector-based gene therapies.   “Viral vector-based cell and gene th...